<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483301</url>
  </required_header>
  <id_info>
    <org_study_id>MEL0205</org_study_id>
    <nct_id>NCT00483301</nct_id>
  </id_info>
  <brief_title>A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma</brief_title>
  <official_title>A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mt. Sinai Medical Center, Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mt. Sinai Medical Center, Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects, good and/or bad, of Carboplatin and&#xD;
      ABI-007 (Abraxane) in combination with Sorafenib (BAY 43-9006) on Melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this phase II multicenter trial is to:&#xD;
&#xD;
      Measure the response rate (RR) of this combination and schedule in patients with metastatic&#xD;
      melanoma&#xD;
&#xD;
      The secondary objectives are to:&#xD;
&#xD;
      Assess the safety and toxicity of this regimen in this patient population&#xD;
&#xD;
      Determine the 1-year and median PFS of patients treated according to protocol&#xD;
&#xD;
      Determine overall survival (OS)&#xD;
&#xD;
      STUDY DESIGN&#xD;
&#xD;
      This will be a Phase II study single arm study with a two-stage design with a maximum sample&#xD;
      size of 43 patients, 18 in the first stage and 25 in the second stage.&#xD;
&#xD;
      Study duration: A minimum yearly accrual of 10-15 patients/institution is expected.&#xD;
      Therefore, to reach the first stage, the study will take 1.2 to 1.8 years with one&#xD;
      institution, 0.6 to 0.9 years with 2 institutions, and 0.4 to 0.6 years with 3. If the study&#xD;
      continues to full accrual to 43 patients, completion will take 2.9 to 4.3 years with one&#xD;
      institution, 1.4 to 2.2 years with two and 0.96 to 1.43 years with three institutions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective</measure>
    <time_frame>one - two years</time_frame>
    <description>Measure the response rate (RR) of this combination and schedule in patients with metastatic melanoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Objective</measure>
    <time_frame>one-two years</time_frame>
    <description>3.2.1 Assess the safety and toxicity of this regimen in this patient population Determine the 1-year and median PFS of patients treated according to protocol Determine overall survival (OS)</description>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (BAY 43-9006)</intervention_name>
    <description>dosage</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-007(Abraxane)</intervention_name>
    <description>dosage</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of melanoma with measurable disease&#xD;
&#xD;
          -  Patients with stage IV, previously untreated, refractory to initial therapy or&#xD;
             progressing after response to initial therapy&#xD;
&#xD;
          -  Patients with unresectable stage III, including unresectable in-transit metastases&#xD;
&#xD;
          -  Two prior chemotherapy regimen is allowed&#xD;
&#xD;
          -  One prior immunotherapy regimen is allowed&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  Radiation therapy to non-target lesions or to one of multiple target lesions may be&#xD;
             allowed on a case-by-case basis&#xD;
&#xD;
          -  Patients must be past the nadir from previous cytotoxic therapy&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dl, absolute neutrophil count (ANC) &gt; 1,500/mm3, platelet count &gt;&#xD;
             100,000/mm3&#xD;
&#xD;
          -  Total bilirubin within normal limits, ALT and AST &lt; 2.0 x the ULN ( &lt; 5 x ULN for&#xD;
             patients with liver involvement), INR &lt; 1.5 and aPTT within normal limits. Patients&#xD;
             who receive anti-coagulation treatment with an agent such as warfarin or heparin may&#xD;
             be allowed to participate. For patients on warfarin, close monitoring of at least&#xD;
             weekly evaluations will be performed until INR is stable based on a measurement at pre&#xD;
             dose, as defined by the local standard of care.&#xD;
&#xD;
          -  Creatinine &lt; 1.5 x ULN, serum calcium within normal limits&#xD;
&#xD;
          -  Patients with stable brain metastasis who have been treated with either whole brain&#xD;
             radiation or Gamma Knife and have been off steroids for &gt; 4 weeks&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (barrier method of birth control) prior to study entry and for the duration of study&#xD;
             participation. Men and women should use adequate birth control for at least three&#xD;
             months after the last administration of protocol drugs. Women of childbearing&#xD;
             potential must have a negative serum pregnancy test performed within 7 days prior to&#xD;
             the start of treatment.&#xD;
&#xD;
          -  Ability to understand and sign a written informed consent document. All patients must&#xD;
             have a signed informed consent before registration and initiation of therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac disease: Congestive heart failure &gt; class II NYHA.&#xD;
&#xD;
          -  Patients must not have unstable angina (anginal symptoms at rest) or new onset angina&#xD;
             (began within the last 3 months) or myocardial infarction within the past 6 months.&#xD;
&#xD;
          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic&#xD;
             pressure &gt; 90 mmHg, despite optimal medical management.&#xD;
&#xD;
          -  No known severe hypersensitivity or suspected allergy to sorafenib, ABI-007 or any of&#xD;
             the excipients&#xD;
&#xD;
          -  Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude&#xD;
             progressing brain metastasis.&#xD;
&#xD;
          -  Peripheral neuropathy greater than grade II&#xD;
&#xD;
          -  Serious intercurrent medical or psychiatric illness, including serious active&#xD;
             infection&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.&#xD;
&#xD;
          -  Thrombotic or embolic events such as a cerebrovascular accident including transient&#xD;
             ischemic attacks within the past 6 months.&#xD;
&#xD;
          -  Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 weeks of first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Serious non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of first&#xD;
             study drug.&#xD;
&#xD;
          -  Use of St. John's Wort or rifampin (rifampicin)&#xD;
&#xD;
          -  Any condition that impairs patient's ability to swallow whole pills.&#xD;
&#xD;
          -  Any malabsorption problem&#xD;
&#xD;
          -  No treatment for melanoma within the previous 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Lutzky, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mt. Sinai Medical Center Miami Beach Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Steven O'Day</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>June 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <last_update_submitted>May 2, 2012</last_update_submitted>
  <last_update_submitted_qc>May 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mt. Sinai Medical Center, Miami</investigator_affiliation>
    <investigator_full_name>Jose Lutzky</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Abraxane</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>BAY 43-9006</keyword>
  <keyword>Abraxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 20, 2014</submitted>
    <returned>June 19, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

